The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

A new scoping review examines the impact of respiratory bacteria on the severity of respiratory syncytial virus (RSV) ...

During the COVID pandemic, RSV showed a slightly odd pattern: like flu, it basically disappeared in the 2020–2021 season, ...

The technology could be adapted for other common respiratory viruses such as seasonal influenza, avian flu and respiratory syncytial virus (RSV ... also a professor of molecular microbiology and of ...